Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.

Introducing dostarlimab + CP as a first-line treatment for patients with pA/rEC results in minimal budget impact PMPM from a US third-party payers' perspective. Together with the efficacy and safety results from RUBY, these results support the use of dostarlimab + CP as a treatment option.